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Abstract Evidence suggests that many G protein-coupled receptors (GPCRs) are
bound together forming dimers. The implications of dimerisation for cellular sig-
nalling outcomes, and ultimately drug discovery and therapeutics, remain unclear.
Consideration of ligand binding and signalling via receptor dimers is therefore required
as an addition to classical receptor theory, which is largely built on assumptions of
monomeric receptors. A key factor in developing theoretical models of dimer sig-
nalling is cooperativity across the dimer, whereby binding of a ligand to one protomer
affects the binding of a ligand to the other protomer. Here, we present and anal-
yse linear models for one-ligand and two-ligand binding dynamics at homodimerised
receptors, as an essential building block in the development of dimerised receptor
theory. For systems at equilibrium, we compute analytical solutions for total bound
labelled ligand and derive conditions on the cooperativity factors under which multi-
phasic log dose–response curves are expected. This could help explain data extracted
from pharmacological experiments that do not fit to the standard Hill curves that are
often used in this type of analysis. For the time-dependent problems, we also obtain
analytical solutions. For the single-ligand case, the construction of the analytical solu-
tion is straightforward; it is bi-exponential in time, sharing a similar structure to the
well-known monomeric competition dynamics of Motulsky–Mahan. We suggest that
this model is therefore practically usable by the pharmacologist towards developing
insights into the potential dynamics and consequences of dimerised receptors.
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1 Introduction
Mathematical models have long played an important role in analytical pharmacology,
which has its roots in receptor theory (Kenakin 2009; Kenakin and Williams 2014;
Kenakin and Christopoulos 2011; Kenakin 2004; Colquhoun 2006). Much of this the-
ory rests upon assumptions of equilibrium and ligands binding to monomeric receptors.
It is now widely accepted that consideration of binding and signalling dynamics is an
important factor in the drug discovery process (Schuetz et al. 2017). Furthermore,
there is widespread acknowledgement that many receptors may exist (constitutively)
as dimers or higher oligomers (Milligan 2004, 2006, 2013; Milligan and Smith 2007).
Therefore, a theoretical foundation for the study of signalling via dimerised receptors
is required in order to classify, quantify and simulate ligand–receptor interactions and
their signalling outcomes, for both equilibrium and dynamic conditions.
G protein-coupled receptors (GPCRs) are membrane receptors of particular ther-
apeutic importance, since they represent targets for up to approximately 50% of
current drugs (Bridge et al. 2010). These receptors were long thought to exist solely
as monomers, and theoretical models for GPCR signalling have largely been built
around this assumption, in line with classical receptor theory for both equilibrium
and dynamic models (Woodroffe et al. 2009, 2010; Bridge 2009; Bridge et al. 2010).
However, it has been demonstrated and is now widely recognised that GPCRs may
exist and function as dimers and higher-order oligomers (Smith and Milligan 2010;
Milligan 2004, 2006; Bai 2004). The extent to which a ligand bound to one site of
an oligomeric receptor complex affects ligand binding characteristics to other sites is
termed cooperativity, and the effect of cross-dimer (or cross-oligomer) cooperativity
on binding and signalling dynamic responses is yet to be fully elucidated theoretically.
In pursuit of potentially developing drugs which exploit ligand binding and acti-
vation crosstalk at dimeric receptors, many questions remain. For example, what are
the potential advantages (to a cell or tissue) to express dimeric rather than monomeric
receptors? “Expanded pharmacology” possibilities (in terms of binding and activation)
may increase the diversity of potential signalling responses (via G protein coupling
and signalling) towards “fine-tuning” cell responses (Smith and Milligan 2010). Iden-
tifying homodimers and heterodimers and understanding their role in signalling is a
key step towards exploiting oligomerisation in drug discovery (Smith and Milligan
2010; Milligan 2004). The prevalence of GPCR dimers is a subject of debate, but
their capacity for functional outcomes beyond those offered by monomers gives clear
potential for the development of novel therapeutics (Milligan 2013). Indeed, with
respect to classical receptor theory, dimerised receptors may represent “novel recep-
tors” , i.e. receptors whose binding and signalling response profiles are more complex
and offer more targetable therapeutic potential than their constituent protomers alone.
Much needs to be established in terms of differential pharmacology and functional
effects before dimers become tractable drug targets (Milligan 2009); development of
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the theory of dimerised GPCRs is therefore needed (Bai 2004), and we begin here by
presenting mathematical models of ligand binding dynamics.
Mathematical modelling of binding to dimerised GPCRs has largely focused on
equilibrium binding models (Casadó et al. 2007; Chidiac et al. 1997; Durroux 2005;
Franco et al. 2006, 2005, 2007; Ferré et al. 2014), but the dynamics of ligand binding
at such dimers have not been widely modelled. Typically, the equilibrium models yield
analytical solutions for total bound labelled ligand, derived algebraically using mass
action and receptor conservation considerations. Corresponding log dose–response
(logDR) curves for bound ligand may be multiphasic, exhibiting multiple inflections
(Ferré et al. 2014; Casadó et al. 2009; Rovira et al. 2009; Durroux 2005; Chidiac et al.
1997). For models of dimerised receptor binding, this departure from monophasic
logDR curves (typical of monomeric receptor binding) may be quantified by a dimer
cooperativity index (Giraldo 2008; Casadó et al. 2007; Franco et al. 2008), which
relates to the apparent binding cooperativity in the Hill function sense. Within a Hill
function analysis, however, there is the possibility that information is missed due to
the inability of Hill coefficients to distinguish interaction mechanisms (Prinz 2010).
These works appear to be the state of the art in practical GPCR models, while more
mathematically abstract approaches are taken elsewhere: an algebra of dimerisation is
presented in Woolf and Linderman (2004), and generalised multi-site binding models
are analysed in Juška (2008).
Dynamic models of binding and signalling for dimerised receptors are less common
than equilibrium models. Spatial models of the dimerisation process and subsequent
signalling are developed in Mayawala et al. (2006), while dynamics of receptor and
transducer protein dimerisation are studied using an ordinary differential equation
(ODE) model in Vera et al. (2008), wherein it is suggested that homodimerisation
may serve to regulate signalling over multiple timescales. Ligand-induced dimerisa-
tion of VEGF receptors is modelled using ODEs in Mac Gabhann and Popel (2007).
In order to lay the foundations for dynamic modelling of signalling via dimerised
GPCRs, we refer to a more recent study of GPCR ligand binding dynamics (May
et al. 2011). Therein, linear ODE models of single-ligand and competition dynamics
at pre-dimerised homodimeric receptors are presented, with a brief model analysis
and numerical data fitting, without presenting analytical solutions to the ODE sys-
tems. In the current work, we describe a simplified formulation of the May et al.
models and derive their analytical solutions. For the single-ligand model, the solution
structure (bi-exponential in time, reflecting two distinct eigenvalues) is reminiscent of
Motulsky–Mahan competition dynamics at a monomer (Motulsky and Mahan 1984).
In this paper, we develop mathematical models for the dynamics of ligand binding
at pre-dimerised receptors. In Sect. 2, we formulate and solve (analytically) a linear
ODE model for single-ligand (A) binding kinetics at constitutively dimerised recep-
tors. We first relate our model to previous models and find an analytical equilibrium
solution for total bound ligand. From this solution, we derive a condition under which
multiple inflections in the logDR curve appear, in terms of the mechanistic binding
cooperativity coefficient (α). Further, we show that the time-dependent problem has
an analytical solution which may be easily constructed and computed without the need
for numerical ODE solvers and use this solution to simulate the binding dynamics. In
Sect. 3, we extend our model to account for the presence of a second competing ligand
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Fig. 1 Schematic representing
the reactions resulting from the
binding of a single ligand
A + R
ka+
ka−
AR
A + AR
α+ka+
α−ka−
ARA
(B). Again, we relate to previous models and begin by finding the equilibrium solu-
tion. This enables us to derive a condition for multiple inflections in the logDR curve
for total bound ligand A, which this time depends on multiple mechanistic binding
cooperativity coefficients and the concentration of B. The ODE model for competition
dynamics is linear as before, but its analytical solution is more laborious to compute.
We again simulate the binding dynamics to explore the effects of the dynamic coopera-
tivity factors. In Sect. 4, we conclude with a discussion of our main results, underlining
our contribution to the literature, and considering dynamic modelling in the context
of mathematics supporting drug discovery.
2 Initial Model: Single Ligand
2.1 Model Formulation
In this initial model, we consider a single-ligand, A, binding to a pre-dimerised receptor
complex. For the purposes of this paper, we assume all dimers are homodimers and
so consist of two identical receptors bound together. We denote these dimers as R for
simplicity in the model but keep the assumption that ligand molecules can bind to either
side of the dimer. Association and dissociation rates are ka+ and ka−, respectively, and
we assume there is no bias to which protomer the ligand molecule binds to first. As the
second ligand binding may be affected by one side of the dimer being already bound,
we introduce α = α+/α− which represents the equilibrium binding cooperativity,
that is the factor change in affinity for the dimer when it is already ligand bound. The
value α = 1 represents neutral cooperativity, and α > 1 and α < 1 represent positive
and negative cooperativity, respectively. Figure 1 shows the system of biochemical
reactions. Since R represents a dimer, AR is the complex created by a single-ligand
molecule binding to a protomer and AR A is a dual bound receptor.
2.2 Differential Equations
Applying the law of mass action, the binding kinetics are governed by the following
system of ordinary differential equations (ODEs):
d[R]
dt
= ka−[AR] − ka+[A][R], (1a)
d[AR]
dt
= ka+[A][R] − ka−[AR] − α+ka+[A][AR] + α−ka−[AR A], (1b)
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d[AR A]
dt
= α+ka+[A][AR] − α−ka−[AR A], (1c)
Conservation of receptors in the system allows us to give the total concentration of
dimerised receptors as Dtot = [R]+[AR]+[AR A]. We use this to reduce the system to
two ODEs which, taking [A] as a constant, we write in the form of ddt X(t) = MX(t)+f:
d
dt
( [AR]
[AR A]
)
=
(−(ka− + ka+[A] + α+ka+[A]) α−ka− − ka+[A]
α+ka+[A] −α−ka−
)( [AR]
[AR A]
)
+
(
ka+[A]Dtot
0
)
, (2)
with initial conditions
( [AR](0)
[AR A](0)
)
=
(
0
0
)
. (3)
2.3 Equilibrium Analysis
In the spirit of classical receptor theory, we first investigate the equilibrium behaviour
of the system, in particular the effect of the equilibrium cooperativity factor α. The
equilibrium relationships are
[AR] = K A[A][R], (4a)
[AR A] = αK A[A][AR], (4b)
where K A = ka+/ka− is the equilibrium association constant and α = α+/α− is the
equilibrium binding cooperativity. The total concentration of dimers is
Dtot = [R] + [AR] + [AR A]
= [R](1 + K A[A] + αK 2A[A]2), (5)
which we can combine with equations (4) to express the equilibrium concentrations
in terms of parameters only, giving
[R] = 1
1 + K A[A] + αK 2A[A]2
Dtot, (6a)
[AR] = K A[A]
1 + K A[A] + αK 2A[A]2
Dtot, (6b)
[AR A] = αK
2
A[A]2
1 + K A[A] + αK 2A[A]2
Dtot. (6c)
We can clearly see that as [A] → ∞ the concentrations of [R] and [AR] fall to
zero, whereas [AR A] tends to Dtot. The total amount of ligand bound is of primary
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Fig. 2 LogDR curves for α ranging from extreme negative to extreme positive cooperativity. Association
and dissociation rates are kept at ka+ = 1 × 107 M−1 s−1 and ka− = 0.1 s−1, respectively, and Dtot is set
at 1 × 10−10 M. We see that extra inflections appear in Abound when we have very negative cooperativity
interest, since this is often an experimentally measurable quantity (May et al. 2011).
At equilibrium, we have Abound = [AR] + 2[AR A] due to a single-ligand molecule
being bound in [AR] and two-ligand molecules being bound in [AR A]. We therefore
find
Abound = (K A[A] + 2αK
2
A[A]2)
1 + K A[A] + αK 2A[A]2
Dtot. (7)
This result is equivalent to the result (Giraldo 2008) states when discussing a mecha-
nistic model for a single-ligand binding to a dimerised receptor. As the maximal ligand
bound is 2Dtot, we can calculate the EC50 value for Abound (the concentration giving
half-maximal effect) as
A50 = 1K A√α . (8)
Figure 2 shows how the equilibrium cooperativity factor α affects the log dose–
response (logDR) binding relationship. Increasing cooperativity leads to dimers
becoming dual bound for lower concentrations of [A] and lower peaks in [AR]. Fur-
ther, for Abound, biphasic logDR curves with multiple inflections are possible. With
extreme negative cooperativity, we see three inflections in the curve instead of just one.
It can be shown (“Appendix B” ) that the inflection point that appears in all curves is at
the point [A] = 1/K A√α, which in this case is the same value as the EC50 due to the
symmetric nature of the curves. Also, with increased α > 1, we see an approximate
leftward shift in the curve.
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Since the existence of extra inflections depends on α we seek a condition on α for
when these appear. Following the calculation in “Appendix B,” we find that for three
inflections we require
0 < α < 1/16. (9)
We note that this is different from Giraldo’s dimer cooperativity index condition for
apparent cooperativity (Giraldo 2008). From a curve-fitting perspective, α = 1/4 is
mechanistically negatively cooperative, but would give apparent cooperativity in the
Hill function sense (see Giraldo 2008). When (9) holds, the inflection at [A] = A50
changes from a rising inflection point to a falling one and we get two extra inflection
points, one for [A] < A50 and one for [A] > A50 at the points
[A] = 1 − 8α ±
√
(16α − 1)(4α − 1)
2αK A
. (10)
We see in Fig. 2 that this results in a biphasic curve. We note here that a biphasic logDR
curve with three inflections as shown would not be seen for monomeric receptors. An
experimental logDR curve may be suggestive of pre-dimerised receptors and very
negative cooperativity.
2.4 Binding Dynamics–Analytical Solutions
The exact solution to the initial value problems 2, 3 may be constructed by calculating
the eigenvalues of the coefficient matrix and by using the method of undetermined
coefficients (“Appendix D”), or by the method of Laplace transform (as in Motulsky
and Mahan 1984). Both methods give the analytical solutions as:
[AR](t) = ka+[A]Dtot
det(M)
(
λ2(α−ka− + λ1)eλ1t − λ1(α−ka− + λ2)eλ2t
λ1 − λ2 + α−ka−
)
,
(11)
[AR A](t) = α+k
2
a+[A]2 Dtot
det(M)(λ1 − λ2)
(
λ2e
λ1t − λ1eλ2t + λ1 − λ2
)
, (12)
where the eigenvalues of the coefficient matrix M are
λ1 =
(
Tr(M) +
√
Tr(M)2 − 4 det(M)
)
/2, (13a)
λ2 =
(
Tr(M) −
√
Tr(M)2 − 4 det(M)
)
/2, (13b)
and Tr(M) and det(M) are the trace and determinant of M , respectively, given by:
Tr(M) = −((α− + 1)ka− + (α+ + 1)ka+[A]) < 0, (14a)
det(M) = α−k2a− + α−ka−ka+ A + α+(ka+[A])2
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= α−k2a−
(
1 + K A[A] + αK 2A[A]2
)
> 0, (14b)
Our response of primary interest is the total concentration of ligand bound, Abound,
which is given by
Abound(t) = ka+[A]Dtotdet(M)(
λ2(α−ka− + λ1 + 2α+ka+[A])eλ1t − λ1(α−ka− + λ2 + 2α+ka+[A])eλ2t+α−ka−+2α+ka+[A]
λ1 − λ2
)
.
(15)
The solution has two exponential components, meaning we would expect to see bi-
exponential time courses in general. It can be shown (“Appendix C”) that not only
are eigenvalues λ1 and λ2 real and distinct but they are also always negative, since
all parameters in the model are positive. Further, λ1 gives the slow component of the
dynamics, while λ2 gives the fast component. Clearly, as t → ∞, the exponential
components will decay to zero and we recover the equilibrium concentrations as
[AR] = α−ka+ka−[A]Dtot
det(M)
, [AR A] = α+k
2
a+[A]2 Dtot
det(M)
, (16)
giving the total ligand bound at equilibrium as
Abound = ka+[A]Dtotdet(M)
(
α−ka− + 2α+ka+[A]
)
, (17)
equivalent to (6).
Having analytical solutions for the dynamics allows time courses to be plotted
without the need for numerical ODE solvers. This is particularly useful for pharma-
cologists without numerics expertise, allowing them to construct exact solutions for
any parameter values in software packages such as Microsoft Excel or GraphPad Prism
(accepted). In this respect, the dynamics for our dimer binding model have the same
analytical structure as Motulsky–Mahan dynamics (Motulsky and Mahan 1984). In
“Appendix H,” we show a sample MATLAB code for construction of the analytical
solution.
2.5 Results
Here we present numerical results which demonstrate the effects of cooperative dynam-
ics across dimerised receptors. Figure 3 shows the binding of ligand A to the dimerised
receptor [R] with the ligand being added as a constant quantity. Initially, ligand
molecules bind singly to dimers, creating an increase in [AR]. As time increases, a
positive cooperativity factor means that the chance of a second ligand molecule bind-
ing to the singularly bound dimer is increased; thus, [AR A] increases. This increase
in [AR A] also has the effect of reducing [AR] which then falls towards zero. Hence,
we see a peak in [AR]. In fact, this peak becomes a point of interest as we move on
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Fig. 3 The binding of ligand A to a pre-dimerised receptor results in a surge in [AR], while positive
cooperativity leads to most dimers becoming dual bound. Parameter values are ka+ = 1 × 107 M−1 s−1
and ka− = 0.1 s−1 for association and dissociation rates while keeping [A] constant at 1 × 10−8 M. Also
α+ = 2 and α− = 0.01, giving positive cooperativity, and Dtot = 1 × 10−10 M
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Fig. 4 Binding dynamics with varying [A] in the system. With high levels of [A], we no longer see peaks
in [AR]. Here, ka+ = 1 × 107 M−1 s−1 and ka− = 0.1 s−1, α+ = 2 and α− = 0.01 with Dtot =
1 × 10−10 M
to look at Fig. 4. In this, we consider a range of values of [A] and study the effect this
has on the binding dynamics. It is clear that not only does Abound increase to a higher
equilibrium concentration as [A] increases, but the equilibration timescale is shorter.
For low [A], [AR] apparently approaches equilibrium monotonically, whereas a peak
in [AR](t) occurs for high concentrations of A. The time at which a possible local
extremum occurs is
t = −
log
(
α−ka−+λ1
α−ka−+λ2
)
λ1 − λ2 . (18)
For a peak in [AR](t) (see “Appendix E”), we require
ka+[A] > α−ka−, (19)
and the corresponding peak concentration of [AR] is
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Fig. 5 Binding dynamics with varying α. As we move from positive to negative cooperativity, we see a
more pronounced peak in [AR] with Abound tending to lower concentrations. Here, ka+ = 1×107 M−1 s−1
and ka− = 0.01 s−1, [A] = 1 × 10−8 M, Dtot = 1 × 10−10 M. We fix α− = 1 so cooperativity varies
via α+
[AR]peak = ka+[A]Dtotdet(M)
⎛
⎝−(α−ka− + λ1)
(
α−ka− + λ1
α−ka− + λ2
) λ1
λ2−λ1 + α−ka−
⎞
⎠ .
(20)
In Fig. 5, we study the effect of α on Abound(t). Clearly, the binding rate for a second
ligand to the dimer increases and decreases for positive and negative cooperativity,
respectively. We see a peak in [AR](t) whose timing and concentration are dependent
on α+. As α+ increases, the peak in [AR] decreases and occurs earlier. Both [AR A]
and Abound increase as α+ increases.
3 Two-Ligand System
3.1 Model Formulation
We now introduce a second ligand, B, to the system. The rationale for this is that quan-
tification of effects of unlabelled ligands can be achieved by competition experiments
with labelled and unlabelled ligands, as seen in previous studies involving monomeric
and dimeric receptors (Motulsky and Mahan 1984; May et al. 2011; Durroux 2005;
Franco et al. 2006). The kinetics of this system are key in highlighting and quantifying
allosteric interactions across dimerised receptors, as indicated by May et al. (2011),
who discuss the influence of an unlabelled ligand on the dissociation (washout) kinetics
of a labelled ligand, when dimers are present.
We denote β = β+/β− as the influence a protomer bound by ligand B has on a
second B molecule binding, and γ = γ+/γ− as the cooperativity factor describing
the interaction between A and B bound receptors. This extended system gives a set of
six reactions, as can be seen in Fig. 6. Taken together, these reactions correspond to a
single face of the model schematic developed by Franco et al. (2006).
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A + R
ka+
ka−
AR B + R
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A + AR
α+ka+
α−ka−
ARA B + AR
γ+kb+
γ−kb−
ARB
A + BR
γ+ka+
γ−ka−
ARB B + BR
β+kb+
β−kb−
BRB
Fig. 6 Schematic showing the binding possibilities with two ligands in the system
3.2 Differential Equations
As the total concentration of receptors is given by
Dtot = [R] + [AR] + [B R] + [AR A] + [ARB] + [B RB], (21)
we may eliminate [R] to give a system of five linear ODEs:
d[AR]
dt
= − (ka+[A] + ka− + α+ka+[A] − γ+kb+[B])[AR] − ka+[A][B R]
+ (α−ka− − ka+[A])[AR A] + (γ−kb− − ka+[A])[ARB]
− ka+[A][B RB] + ka+[A]Dtot, (22a)
d[B R]
dt
= − kb+[B][AR] − (kb+[B] + kb− + γ+kb+[A] + β+kb+[B])[B R]
− kb+[B][AR A] + (γ−kb− − kb+[B])[ARB]
+ (β−kb− − kb+[B])[B RB] + kb+[B]Dtot, (22b)
d[AR A]
dt
= α+ka+[A][AR] − α−ka−[AR A], (22c)
d[ARB]
dt
= γ+kb+[B][AR] + γ+ka+[A][B R]
− γ−kb−[ARB] − γ−ka−[ARB], (22d)
d[B RB]
dt
= β+kb+[B][B R] − β−kb−[B RB]. (22e)
with initial conditions
⎛
⎜⎜⎜⎜⎝
[AR](0)
[B R](0)
[AR A](0)
[ARB](0)
[B RB](0)
⎞
⎟⎟⎟⎟⎠ =
⎛
⎜⎜⎜⎜⎝
0
0
0
0
0
⎞
⎟⎟⎟⎟⎠ . (23)
We note that this system is a simplification of the one developed by May et al. (2011)
(see “Appendix A”).
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3.3 Equilibrium Analysis
Once the system reaches equilibrium, we have the set of relations
[AR] = K A[A][R], [B R] = K B[B][R], (24a)
[AR A] = αK 2A[A]2[R], [ARB] = γ K A K B[A][B][R],
[B RB] = βK 2B[B]2[R]. (24b)
The receptor conservation law therefore gives that
Dtot = [R](1 + K A[A] + K B[B] + αK 2A[A]2
+ γ K A K B[A][B] + βK 2B[B]2). (25)
Here we consider, as in May et al. (2011), competition experiments where ligand A is
labelled and ligand B is unlabelled. We can clearly see that, providing [B] is fixed,
[R], [AR], [B R], [ARB], [B RB] → 0, and [AR A] → Dtot as [A] → ∞. (26)
The total concentration of bound ligand A (assumed an experimentally measurable
quantity) is
Abound = [AR] + 2[AR A] + [ARB], (27)
which, using Eqs. (24) and (25), gives
Abound = K A[A] + 2αK
2
A[A]2 + γ K A K B[A][B]
1 + K A[A] + K B[B] + αK 2A[A]2 + γ K A K B[A][B] + βK 2B[B]2
Dtot.
(28)
As the maximal Abound for varying [A] remains as 2Dtot, we calculate the EC50 for
Abound as
A50 = 1K A
√
1 + K B[B] + βK 2B[B]2
α
, (29)
which we note is independent of the A-B cooperativity factor γ . In Figs. 7, 8, 9, we
show the effects of each of the cooperativity factors α, β, γ in turn. In each case, we
plot logDR curves for Abound for a range of values for [B].
In Fig. 7, we consider a range of values of α, fixing β and γ . Again we see extra
inflections for low values of α, similarly to the single-ligand system. While molecules
of B bind to AR to form ARB complexes, such a low α means that very few molecules
of A bind to AR; thus, [AR A] remains low, unless [A] is sufficiently large. For
[A] → ∞, both [AR] and [ARB] → 0 regardless of α, giving local maxima in the
logDR curves for these two variables (see individual species plots in Fig. 17). Very
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Fig. 7 LogDR curve for varying α+ shows extra inflections when we have low A-A cooperativity regard-
less of [B]. Plot parameters are ka+ = kb+ = 1 × 107 M−1 s−1, ka− = kb− = 0.1 s−1, [A] =
1 × 10−8M, Dtot = 1 × 10−10 M. All other cooperativity values are set to 1
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Fig. 8 LogDR curve for varying β+ shows extra inflections appear when we have both low B-B cooper-
ativity and low [B]. Plot parameters are ka+ = kb+ = 1 × 107 M−1 s−1, ka− = kb− = 0.1 s−1, [A] =
1 × 10−8 M, Dtot = 1 × 10−10 M. All other cooperativity values are set to 1
small α requires very large [A] to effect this downturn in [AR] and [ARB], giving
plateaus at the maximal response in the logDR for [AR] and [ARB]. It is these plateaus
that change the nature of the original inflection point for Abound, as well as creating
two extra inflections.
Figure 8 shows the effect of varying the B-B cooperativity factor, β. We see extra
inflections appearing for conditions of both low β and high [B]. For high [B] and small
β < 1, a relatively large proportion of receptor will be in [B R] complexes, unless [A]
is sufficiently large. Again, corresponding logDR curves for [AR] and [ARB] exhibit
local maxima (see Fig. 10).
In Fig. 9, we show the effects of A-B cooperativity γ and see that, for extra inflec-
tions, γ is required to be high as opposed to low. We again require there to be a high
concentration of B in the system. The individual species curves in Fig. 11 again show
the requirement of sufficiently large [A] for a downturn in [AR] and [ARB], but this
time with the largest [ARB] values corresponding to large γ .
Investigating these extra inflections in Abound (“Appendix G”), we find that there is
always an inflection point at
[A] = 1
K A
√
1 + K B[B] + βK 2B[B]2
α
. (30)
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Fig. 9 LogDR curve for varying γ+ shows extra inflections when we have high A-B cooperativity as
well as low [B]. Plot parameters are ka+ = kb+ = 1 × 107 M−1 s−1, ka− = kb− = 0.1 s−1, [A] =
1 × 10−8 M, Dtot = 1 × 10−10 M. All other cooperativity values are set to 1
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Fig. 10 Individual species plots for a varying β. Plots were created with parameters K A = K B =
108 M−1, α = γ = 1, [B] = 10−5 M, Dtot = 10−10 M
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Fig. 11 Individual species plots for a varying γ . Plots were created with parameters K A = K B =
108 M−1, α = β = 1, [B] = 10−8 M, Dtot = 10−10 M
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Fig. 12 In the time course plot, we see peaks in both [AR] and [B R]. Parameter values: ka+ = kb+ =
1 × 107 M−1 s−1, ka− = kb− = 0.1 s−1, α+ = β+ = γ+ = 2, α− = β− = γ− = 0.01, [A] =
1 × 10−8 M, [B] = 2 × 10−8 M, Dtot = 1 × 10−10 M
We further find that extra inflections appear under the condition
16α(1 + K B[B] + βK 2B[B]2) < (γ K B[B] + 1)2. (31)
Again we have an extra inflection at either side of the original one, at the points
[A] = m
2 − 8αn ± √(m2 − 16αn)(m2 − 4αn)
2αK Am
, (32)
where m = 1 + γ K B[B] and n = 1 + K B[B] + βK 2B[B]2.
3.4 Time Course Results
Analytical solutions for the system (22) are theoretically possible, given that the system
is linear. However, the task of computing eigenvalues exactly becomes laborious and
impractical; we instead construct the solutions by numerical evaluation of the eigen-
values. A numerical ODE solver could also be used. Here we present time course
simulations for two-ligand competition.
In Fig. 12, we show time courses for each receptor state, for conditions of positive
A-A, A-B and B-B cooperativities. We note [AR] and [AR A] dynamics similar to
the single-ligand problem. Initially, a single-ligand molecule binds to one of the free
receptors in the dimer, increasing [AR] before the positive cooperativity factor soon
after binds a second ligand molecule, thus increasing [AR A] and lowering [AR].
In Fig. 13, we see the effect α has on the time course dynamics of the system. We
look at a range of values of α while keeping β and γ fixed, giving neutral cooperativity.
It is clear that regardless of the A-A cooperativity, we get peaks in both [AR] and [B R].
As α increases, the peak in [B R] is lower and the peak in [AR] is later and higher. As
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Fig. 13 As α+ increases, the peak in [AR] decreases, while the peak in [B R] becomes more pronounced.
Parameter values: ka+ = kb+ = 1 × 107 M−1 s−1, ka− = kb− = 0.1 s−1, [A] = 1 × 10−8 M, [B] =
2 × 10−8 M, Dtot = 1 × 10−10 M. All other cooperativity factors are set to 1
α increases, we also see that [AR A] increases and both [ARB] and [B RB] decrease.
Further, peaks are apparent in [ARB] and, for large α, in [B RB].
In Fig. 14, we vary cooperativity factor β. Non-monotonic behaviour is clearly
shown for all receptor states except [B RB], and the potential for non-monotonic
signal Abound is clearly demonstrated.
In Fig. 15, we demonstrate the effect of varying γ . As molecules of A and B become
bound to free receptors, we again see [AR] and [B R] increase. With small γ , a second
A or B molecule causes [AR A] and [B RB] to increase, while [ARB] remains low.
As γ increases past neutral cooperativity, we begin to see instead that it is the alternate
ligand that binds to singularly bound receptors, meaning that [ARB] increases, while
[AR A] and [B RB] remain low.
4 Discussion
In this paper, we have presented dynamic models of ligand binding to pre-dimerised
GPCR homodimers, for both a single-ligand and two-ligand competition. The models
are linear ODE systems, allowing analytical solutions for time-dependent and equi-
librium responses. The model formulation, solution and results serve as a contribution
to the field of pharmacological modelling and are expected to be of practical use,
given the ease with which we can compute solutions. In particular, the bi-exponential
single-ligand binding kinetics show a similar model solution structure to the widely
used Motulsky–Mahan model for competition binding at monomers (Motulsky and
Mahan 1984). We therefore propose that this model can be adopted, interpreted and
implemented with relative ease by pharmacologists, and as such, we have provided a
recipe for computational solution.
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Fig. 14 As β increases, the peak in [B R] decreases, while the peak in [AR] becomes more pronounced.
Parameter values: ka+ = kb+ = 1 × 107 M−1 s−1, ka− = kb− = 0.1 s−1, [A] = 1 × 10−8, [B] =
2 × 10−8, Dtot = 1 × 10−10 M. All other cooperativity factors are set to 1 so cooperativity is neutral for
A-A and A-B and B-B cooperativity depends solely on β+
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Fig. 15 As γ increases, the peak in both [AR] and [B R] decreases. Parameter values: ka+ = kb+ =
1 × 107 M−1 s−1, ka− = kb− = 0.1 s−1, [A] = 1 × 10−8 M, [B] = 2 × 10−8 M, Dtot = 1 × 10−10 M.
All other cooperativity factors are set to 1 so cooperativity is neutral for A-A and B-B and A-B cooperativity
depends solely on γ+
Time course computation for our models is straightforward, given the analyt-
ical solutions we have developed. However, there are interesting features in the
equilibrium logDR curves for the experimental readout (signal) Abound. We have noted
the possibility for multiple inflections in logDR curves, for both single- and two-ligand
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binding. Multiphasic features in logDR curves are not reproducible by standard Hill
functions (Veroli et al. 2015) which only support single inflection curves. For single-
ligand binding, multiphasic logDR curves theoretically rule out monomeric receptor
binding as the only ligand binding mechanism; such experimental data therefore would
suggest another binding setup, possibly due to dimeric receptors. The existence of
multiple inflections depends on the level of cooperativity across a dimerised receptor,
and importantly we are able to give a condition on the single-ligand cooperativity
factor for a three-inflection curve (9). The practical use of this condition is clearly
in assessing the sign and magnitude of cooperativity towards quantitative classifica-
tion of drug–receptor interactions. Given that Hill functions are not suitable for fully
characterising multiphasic logDR curves (Veroli et al. 2015), our analysis here goes
beyond dimer cooperativity indices which stem in part from cooperativity in the Hill
function sense (Giraldo 2008); the present work concerns mechanistic cooperativity
which is explicit in the original model schematic, as opposed to empirical measures
from a more limited model. In Veroli et al. (2015), it is noted that multiphasic logDR
curves have particular importance in a number of contexts including cancer phar-
macology, and effort should be made to move beyond Hill function fitting wherever
possible.
Two-ligand competition at GPCR homodimers has previously been discussed and
modelled (May et al. 2011). In addition to the therapeutic relevance of agonist–
antagonist competition (May et al. 2011; Bridge et al. 2010), for homodimeric
receptors, dissociation kinetic assays may represent a more sensitive forum for detect-
ing negative cooperativity than logDR analysis alone. As such, we have reduced
the model of May et al. (2011) and outlined the analytical solution structure for
the time-dependent problem. Further, considering a system with a labelled ligand
A and an unlabelled ligand B, we are able to find conditions on [B] and the three
cross-dimer cooperativity factors for multiple inflections in the logDR curve for
Abound (Eq. 31), which again is designed to aid interpretation of experimental data
and clear identification of parameter regimes which may have therapeutic signifi-
cance.
Our simple models of ligands binding to constitutive homodimers, and particularly
the explicit statement and elucidation of analytical results, represent an important
addition to receptor theory. We remark that this should be considered only the foun-
dation of the theory for binding and activation dynamics of GPCR dimers. There is
a clear pathway for building on this foundation to expand upon this model towards
simulating and understanding the potential diversity binding and signalling outcomes
of non-monomeric receptors. In particular, the following natural extensions and con-
siderations should be explored in future work.
1. Heterodimeric GPCRs are widely acknowledged to exist (Smith and Milligan
2010; Milligan 2004, 2006, 2009). Here, we have reduced the model of May
et al. (2011) using the symmetry inherent in their homodimer model, resulting
in a clean formulation amenable to algebraic manipulation. Extension to a more
general model which will encompass heterodimers will require reversion to the
May et al. schematic, but with an implicit asymmetry which will allow for an
“extra level of complexity” (Bai 2004).
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2. Higher-order complexes may exist (Smith and Milligan 2010; Juška 2008), and
while a general functional signalling model for an nth-order oligomer may be
impractical, a ligand binding model of the type developed in the current work
should be possible and may be valuable in distinguishing between orders of
oligomer.
3. Here, we have assumed that all dimeric receptors are constitutively produced, are
the only receptor entities and have not considered the dimerisation process itself.
However, a mixture of monomers, dimers and higher oligomers may exist (Smith
and Milligan 2010; Milligan 2004), and ligand-induced effects on the dimerisation
process have also been noted for GPCRs (Smith and Milligan 2010; Bai 2004) and
other receptors (Mac Gabhann and Popel 2007). Therefore, we propose to expand
the model to include constitutive and ligand-induced dimerisation dynamics. This
will allow theoretical investigation of questions put forth in Milligan (2004) regard-
ing the effects of fraction of receptors which are dimers, dynamics and lifetime
of dimerisation and the effect of ligands. Further modelling in this direction will
draw on dimerisation models (Vera et al. 2008; Mac Gabhann and Popel 2007),
towards a general, hybrid model for constitutive and ligand-induced dimers and
ligand binding. Further complexity may be possible within a dimer population,
whereby only a fraction of dimers may support cross-dimer crosstalk (Durroux
2005).
4. In keeping with classical analytical pharmacology approaches, we have first con-
sidered models for ligand binding; the cooperativity factors α, β, γ are binding
cooperativities. A diverse range of pharmacological effects is theoretically possible
from dimeric receptors, in terms of receptor activation and signalling dynam-
ics (Milligan 2004). Much is yet to be understood about signalling downstream
of dimerised receptors, and how to distinguish between ligand–receptor level
crosstalk and downstream crosstalk when interpreting experimental data (Milligan
2006, 2009; Chabre et al. 2009). A natural extension of our model will include
receptor activation (Giraldo 2008), G protein binding (Milligan 2009; Bai 2004),
and ultimately G protein activation and cycling (Woodroffe et al. 2010; Bridge
2009). In moving towards simulating downstream functional effects, new mod-
elling studies will require consideration of cross-dimer cooperativity in (i) ligand
binding, (ii) receptor activation and (iii) G protein binding.
5. Beyond simulating and using our theoretical results to identify parameter ranges,
our models will be useful for parameter estimation to return best-fit parameter
values to experimental data, as in May et al. (2011). Considering time course data
for ligand binding, and possibly washout experiments, it is important to determine
which of the model’s unknown kinetic parameters are theoretically identifiable
from the given readout. In addition to model fitting with any available data and
pseudo-experimental data, using methods such as genetic algorithms (Ashyraliyev
et al. 2009), an important (but often overlooked) computation in bio-modelling
is that of structural identifiability analysis (SIA). We propose to investigate the
identifiability properties of our linear models using Laplace transform methods
(Godfrey 1986). While beyond our scope here, this is an important avenue of
investigation, given that in May et al. (2011), an initial parameterisation of the
model therein suggests a non-identifiability issue; estimated equilibrium cooper-
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Fig. 16 Binding then washout experiments, for labelled ligand A and unlabelled ligand B, varying [B].
Firstly binding of A in the absence of B, then dissociation of A, with A being washed out, with varying
concentrations of B. The dissociation curves depend on [B], indicating cooperativity across the dimer
(such a result would not be seen for monomeric receptor). Parameter values: ka+ = 1 × 107 M−1 s−1,
ka− = 0.03 s−1, [A] = 3 × 10−9M, kb+ = 1 × 107 M−1 s−1, kb− = 0.01 s−1, α+ = 0.005, α− =
1, β+ = 1, β− = 10, γ+ = 1, γ− = 10. All three equilibrium cooperativities are negative, in qualitative
agreement with (May et al. 2011)
ativities are reported rather than all individual kinetic constants. The analysis in
May et al. (2011) further suggests that a combination of association and washout
experiments will be useful in estimating kinetic parameters relating to dimerised
receptor binding. The simplified models presented in the current work will be used
to simulate such experiments, and a detailed SIA will be performed towards param-
eterising ligand–dimer interactions. In Fig. 16, we show an initial simulation of
binding followed by washout, in qualitative agreement with the results presented
in May et al. (2011).
The current work provides a theoretical foundation for the study of ligands bind-
ing dimerised receptors. We consider this theory as a vital step towards the potential
exploitation of dimerised receptors in a therapeutic and drug discovery context. Under-
standing the functional, physiological and therapeutic significance of receptor dimers
is an ongoing challenge (Smith and Milligan 2010), with some questions still out-
standing over the possible requirement of dimerisation for receptor function (Milligan
2004). Given the broad appreciation of GPCR dimerisation, it is now widely accepted
that dimers are true drug receptors, and cross-dimer binding and activation coop-
erativity gives rise to a “new kind of pharmacological target” (Ferré et al. 2014)
whose allosteric cooperativity is key. So-called dual molecules can be used in target-
ing dopamine–adenosine heterodimers in the treatment of Parkinson’s disease, while
it is suggested that opioid–cannabinoid heterodimers could be targeted for pain relief
(Franco et al. 2008). Mathematical modelling will undoubtedly continue to be a key
tool in simulating and quantifying in vitro ligand–receptor interactions and towards
understanding of in vivo dynamics. In view of the potential functional diversity of
dimerised receptors, the further development of dimerisation dynamics as a field of
receptor theory is a crucial mathematical challenge towards drug discovery.
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A Simplification of the May et al. Model
System (22) is seen to be a simplification of the model developed by May et al. (2011),
equivalent by taking
ka+ = k˜a+2 , ka− = k˜a− kb+ =
k˜b+
2
, kb− = k˜b−, (33)
α+ = 2α˜+, α− = α˜−2 , β+ = 2β˜+,
β− = β˜−2 , γ+ = 2γ˜+, γ− =
γ˜−
2
, (34)
noting that
[AR] = ˜[AR]
2
, [B R] = ˜[B R]
2
, [ARB] = ˜[ARB]
2
, (35)
where a tilde denotes a parameter or variable in the May et al. (2011) model.
B Extra Inflections in the Single-Ligand Abound Curve
In Fig. 2, we saw extra inflections in the logDR curve for Abound. We investigate these
and derive the condition given in Eq. (9). Writing Abound in terms of X = K A[A] for
simplification, we have
Abound = X + 2αX
2
1 + X + αX2 Dtot. (36)
To investigate the inflections, we require d
2 Abound
dY 2 where
Y = log10[A] =
ln
( X
K A
)
ln 10
, (37)
(and X = K A10Y ). Using Di Bruno’s Johnson (2002) formula for the chain rule for
second derivatives, we find
d2 Abound
dY 2
=
(
dX
dY
)2
.
d2 Abound
dX2
+ d
2 X
dY 2
.
dAbound
dX
. (38)
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Calculating each term individually, we have
dX
dY
= K A10Y ln 10 = X ln 10, (39)
d2 X
dY 2
= K A10Y (ln 10)2 = X (ln 10)2, (40)
dAbound
dX
= 1 + 4αX + αX
2
(1 + X + αX2)2 Dtot, (41)
d2 Abound
dX2
= −2(1 − 2α + 3αX + 6α
2 X2 + α2 X3)
(1 + X + αX2)3 Dtot. (42)
Substituting into (38), and after some simplification, we find
d2 Abound
dY 2
= X (ln 10)
2(1 + (8α − 1)X + (α − 8α2)X3 − α2 X4)
(1 + X + αX2)3 Dtot. (43)
To locate the possible inflection points, we find zeros of d2 Abound/dY 2, which occur
when
X (1 + (8α − 1)X + (α − 8α2)X3 − α2 X4) = 0,
⇒ −X (αX2 − 1)(1 − X + 8αX + αX2) = 0. (44)
This gives the trivial solution at X = 0 and solutions at
X = ± 1√
α
. (45)
However, we are only interested in positive solutions, so we conclude that we always
have an inflection point at X = 1/√α, that is when [A] = 1/K A√α. We note that this
is the same concentration of [A] that gives half the maximal response. Other possible
inflections occur for roots X > 0 of the quadratic equation
1 − X + 8αX + αX2 = 0, (46)
which gives solutions at
X± = 1 − 8α ±
√
(8α − 1)2 − 4α
2α
= 1 − 8α ±
√
(16α − 1)(4α − 1)
2α
. (47)
We see that we get a repeated root if
(16α − 1)(4α − 1) = 0, (48)
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that is when α = 1/16 or α = 1/4. However, we see that the root is only positive for
α = 1/16. To get real and distinct solutions, we require
(16α − 1)(4α − 1) > 0, (49)
that is when α > 14 or when α <
1
16 . We also need to confirm whether the roots are
positive or negative under these conditions. So first noting that
(1 − 8α)2 − 4α > 0, (50)
⇒ (1 − 8α)2 > 4α, (51)
⇒
√
(1 − 8α)2 − 4α < 8α − 1. (52)
Now if α < 1/16, then 1 − 8α > 1 − 1/2 = 1/2 > 0; thus, we have two positive
roots under this condition. However, if α > 1/4, then 1 − 8α < 1 − 2 = − 1 < 0;
hence, under this condition we get two negative roots. So we conclude that we get two
possible extra inflection points under the condition 0 < α < 1/16.
To confirm that these are inflection points and classify the type of inflection, we
consider d3 Abound/dY 3. Using the Di Bruno formula (see Johnson (2002)) for higher
derivatives, or MATLAB’s Symbolic Toolbox, we find:
d3 Abound
dY 3
=
X (ln 10)3
(
1 + (16α − 4)X + (1 − 13α)X2 + (8α − 64α2)X3
+ (α − 13α2)X4 + (16α3 − 4α2)X5 + α3 X6
)
(1 + X + αX2)4 Dtot.
(53)
For the EC50 value, at X = 1/√α, and substituting this into the third derivative. After
some simplification, we have
− (ln 10)
3(8α − 2√α)
(2
√
α + 1)2 Dtot, (54)
which we can see is positive for any 0 < α < 1/16 and negative for any α > 1/16.
Similarly for the extra inflections, we found at X = τ1 and X = τ2 when α < 1/16.
Substituting both of these in results in a value of
(ln 10)3(16α − 1)
8(4α − 1)2 Dtot, (55)
which clearly gives a negative result for any 0 < α < 1/16.
Looking at these results, we can see that if α > 1/16, we have the single inflection
point, which in this case has a concavity that changes from convex to concave. How-
ever, when 0 < α < 1/16, this inflection point reverses and so is concave changing to
convex. In this case, we also get the two extra points, with each of those being convex
changing to concave at the point.
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C Confirming the Eigenvalues of the Coefficient Matrix are Real,
Distinct and Negative
Before we can solve the system of equations to give analytical solutions, we need to
know whether the eigenvalues, given in Eq. (13), of the coefficient matrix M are real
and distinct so we can determine the form of the general solution. Being able to state
whether these are also positive or negative allows us to analyse these solutions. The
eigenvalues are defined as
λ1,2 = Tr(M) ±
√
Tr(M)2 − 4 det(M)
2
= Tr(M) ±
√
Tr(M)2 − 4 det(M)
2
, (56)
so we can see that the discriminant is
D = Tr(M)2 − 4 det(M). (57)
Expanding D, we have
D = Tr(M)2 − 4 det(M),
= (α− − 1)2k2a− − 2(α− − 1)(α+ + 1)ka+ka−[A]
+ (α+ + 1)2k2a+[A]2 − 4α+k2a+[A]2 + 4α+α−ka+ka−[A],
= (α− − 1)2k2a− − 2(α+α− + α− − α+ − 1)ka+ka−[A]
+ (α+ + 1)2k2a+[A]2 − 4α+k2a+[A]2 + 4α+α−ka+ka−[A],
= (α− − 1)2k2a− − 2(α+α− + α− − α+ − 1)ka+ka−[A]
+ (α+ − 1)2k2a+[A]2 + 4α+α−ka+ka−[A],
= (α− − 1)2k2a− + 2(α+α− − α− + α+ + 1)ka+ka−[A]
+ (α+ − 1)2k2a+[A]2,
= (α− − 1)2k2a− + 2((α− − 1)(α+ − 1) + 2α+)ka+ka−[A]
+ (α+ − 1)2k2a+[A]2,
= ((α− − 1)ka− + (α+ − 1)ka+[A])2
+ 4α+ka+ka−[A],
> 0. (58)
Hence, D is always positive, providing that all parameters are positive.
We can also show that both λ1 and λ2 are always negative. First noting that Tr(M)
is negative due to all terms being negative, and
Tr(M)2 − 4 det(M) > 0 (59)
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⇒ Tr(M)2 > 4 det(M) (60)
⇒
√
Tr(M)2 − 4 det(M) < Tr(M). (61)
Thus, it is clear that both Tr(M) + √Tr(M)2 − 4 det(M) < 0 and Tr(M) −√
Tr(M)2 − 4 det(M) < 0; hence, both eigenvalues are negative.
D Analytical Solutions for the Single-Ligand Dynamics
One of the main motivations for this paper is to be able to give exact solutions to the
system, allowing for simulations to be run easily; hence, in this appendix we derive
these solutions as stated in Eqs. (11) and (12). To find a solution to the system, we
first find the eigenvalues of the coefficient matrix, M .
λ1,2 = Tr(M) ±
√
Tr(M)2 − 4 det(M)
2
. (62)
The eigenvectors corresponding to eigenvalues λ1 and λ2 are
v1 =
(
λ1 + α−ka−
α+ka+[A]
)
, v2 =
(
λ2 + α−ka−
α+ka+[A]
)
. (63)
Thus, we can state that a solution to the system will be of the form
X(t) = c1v1eλ1t + c2v2eλ2t + Xp(t), (64)
where Xp(t) is a particular solution, found by solving MX + f = 0, thus
Xp = ka+[A]Dtot
det(M)
(
α−ka−
α+ka+[A]
)
. (65)
As t → ∞, all other terms in the solution tend to zero, due to λ1,2 always being nega-
tive; thus, the particular solution tells us what [AR] and [AR A] will be at equilibrium.
We now use the initial conditions to solve the system and find the coefficients c1 and
c2, as
C =
(
c1
c2
)
= ka+[A]Dtot
det(M)(λ1 − λ2)
(
λ2
−λ1
)
. (66)
We find the solutions
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[AR](t) = ka+[A]Dtot
det(M)
(
λ2(α−ka− + λ1)eλ1t − λ1(α−ka− + λ2)eλ2t
λ1 − λ2 + α−ka−
)
,
(67)
[AR A](t) = α+k
2
a+[A]2 Dtot
det(M)(λ1 − λ2)
(
λ2e
λ1t − λ1eλ2t + λ1 − λ2
)
. (68)
E A Condition for Existence of a Peak in [AR](t)
As we saw in Figs. 3, 4, we sometimes get a peak in [AR](t). In this appendix, we
investigate these peaks to find a condition Eq. (19) for peak existence and calculate
this peak concentration Eq. (20) is. The peak time is given by Eq. (18)
t = −
ln
(
α−ka−+λ1
α−ka−+λ2
)
λ1 − λ2 . (69)
For peak existence, we therefore require
α−ka− + λ1
α−ka− + λ2 > 0, (70)
where λ2 < λ1 < 0. Hence, we require, for a positive peak time,
0 <
α−ka− + λ1
α−ka− + λ2 < 1,
which requires that
α−ka− + λ1 < 0.
Since λ1 = −(α−+1)ka−−(α++1)ka+[A]+
√
D
2 , where D is the discriminant for the coeffi-
cient matrix, we find our requirement to be
0 < (α+ + 1)ka+[A] − (α− + 1)ka− <
√
D,
which eventually gives
α− < K A[A]. (71)
To evaluate the peak concentration [AR], we take Eq. (18)
t = −
log
(
α−ka−+λ1
α−ka−+λ2
)
λ1 − λ2 . (72)
and substituting the peak time into Eq. (11), giving
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ka+[A]Dtot
det(M)
⎛
⎜⎜⎝
λ2(α−ka− + λ1)
(
α−ka−+λ1
α−ka−+λ2
) λ1
λ2−λ1 − λ1(α−ka− + λ2)
(
α−ka−+λ1
α−ka−+λ2
) λ2
λ2−λ1
λ1 − λ2 + α−ka−
⎞
⎟⎟⎠
(73)
= ka+[A]Dtot
det(M)
⎛
⎜⎜⎝
(
λ2(α−ka− + λ1) −
(
α−ka−+λ1
α−ka−+λ2
)
λ1(α−ka− + λ2)
) (
α−ka−+λ1
α−ka−+λ2
) λ1
λ2−λ1
λ1 − λ2 + α−ka−
⎞
⎟⎟⎠
(74)
= ka+[A]Dtot
det(M)
⎛
⎜⎜⎝
(λ2(α−ka− + λ1) − λ1(α−ka− + λ1))
(
α−ka−+λ1
α−ka−+λ2
) λ1
λ2−λ1
λ1 − λ2 + α−ka−
⎞
⎟⎟⎠ (75)
= ka+[A]Dtot
det(M)
⎛
⎜⎜⎝
(λ2 − λ1)(α−ka− + λ1)
(
α−ka−+λ1
α−ka−+λ2
) λ1
λ2−λ1
λ1 − λ2 + α−ka−
⎞
⎟⎟⎠ (76)
= ka+[A]Dtot
det(M)
⎛
⎝−(α−ka− + λ1)
(
α−ka− + λ1
α−ka− + λ2
) λ1
λ2−λ1 + α−ka−
⎞
⎠ (77)
as the corresponding concentration of [AR].
F Individual Species Dose–Response Curves
To further help us understand the behaviour observed in the logDR curves for Abound,
we look to the individual species plots. In Fig. 17, we see plateaus in the logDR curves
of [AR] and [AR A] when we have very low A-A cooperativity. These are the main
contributions to the inflections in Abound.
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Fig. 17 Individual species plots for a varying α. Plots were created with parameters K A = K B = 1 ×
108 M−1/s−1, β = γ = 1, [B] = 10−8 M, Dtot = 10−10
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G Investigating the Extra Inflections in the Two-Ligand Abound curve
Similarly to the single-ligand system, we also get extra inflections in the Abound curve
when we have two ligands in the system. In this appendix, we investigate these to
derive the condition given in Eq. (31) under which we get these extra inflections. We
begin by writing Abound as
Abound = X + 2αX
2 + γ XY
1 + X + Y + αX2 + γ XY + βY 2 Dtot, (78)
where X = K A[A] and Y = K B[B]. For possible inflections, we first calculate
d2 Abound/d Z2 where Z = log10[A] = ln( XK A )/ ln 10. We find
d2 Abound
dZ2
=
X (ln 10)2((βY 2 + Y + 1 − αX2)
((α + αγ Y 2)X2 + (8α(βY 2 + Y + 1) − (1 + γ Y )2)X + (1 + γ Y )(βY 2 + Y + 1))
(1 + X + Y + αX2 + γ XY + βY 2)3
(79)
= X (ln 10)
2(n − αX2)(mn + (8αn − m2)X + αm X2)
(n + m X + αX2)3 (80)
where m = 1 + γ Y and n = 1 + Y + βY 2. Clearly, we have the trivial root at X = 0
as well as a root when
n − αX2 = 0, (81)
that is when
X = ±
√
n
α
. (82)
As we are only interested in positive roots, we conclude that we have a possible
inflection at
Xc =
√
n
α
, (83)
which corresponds to the EC50 concentration. We also get extra roots when
mn + (8αn − m2)X + αm X2 = 0, (84)
which using the quadratic formula gives us
X± = m
2 − 8αn ± √(8α − m2)2 − 4αm2n
2αm
(85)
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= m
2 − 8αn ± √(m2 − 16αn)(m2 − 4αn)
2αm
. (86)
We see that we get a single, real root when
(m2 − 16αn)(m2 − 4αn) = 0, (87)
that is when m2 = 16αn or m2 = 4αn. However, we see that if m2 = 4αn, then
X = − 2n/m, hence a negative root. Whereas if m2 = 16αn, then X = 4n/m, so
we have a positive root. Thus, we can conclude that we have a possible inflection at
X = 4n/m under the condition of m2 = 16αn.
Finally, we have two real distinct roots when
(m2 − 16αn)(m2 − 4αn) > 0. (88)
As m2 − 16αn < m2 − 4αn, then this holds if either m2 > 16αn or m2 < 4αn. To
confirm whether these conditions give positive or negative roots, we first note that
(m2 − 8αn)2 − 4αm2n > 0 (89)
⇒ (m2 − 8αn)2 > 4αm2n (90)
⇒
√
(m2 − 8αn)2 − 4αm2n < m2 − 8αn. (91)
Using this, we can state that if m2 > 16αn, then m2−8αn > 16αn−8αn = 8αn > 0;
hence, we have two positive roots. Conversely, if m2 < 4αn, then m2 − 8αn <
4αn − 8αn = − 4αn < 0; hence, both roots are negative. Thus, we can conclude
that we get two positive roots, and possible inflection points, under the condition
m2 > 16αn. That is
(1 + γ Y )2 > 16α(1 + Y + βY 2). (92)
To confirm that these are in fact inflection points, we first confirm that X− < Xc <
X+. First noting that m2 −16αn < m2 −4αn ⇒ (m2 −16αn)2 < (m2 −16αn)(m2 −
4αn) ⇒ m2 − 16αn < √(m2 − 16αn)(m2 − 4αn), then we can state that
X− = m
2 − 8αn − √(m2 − 16αn)(m2 − 4αn)
2αm
(93)
<
m2 − 8αn − (m2 − 16αn)
2αm
(94)
= 8αn
2αm
(95)
= 4n
m
(96)
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=
√
16n2
m2
(97)
<
√
n
α
= Xc. (98)
Thus, we can confirm that X− < Xc. Also
X+ = m
2 − 8αn + √(m2 − 16αn)(m2 − 4αn)
2αm
(99)
>
m2 − 8αn
2αm
(100)
=
√
(m2 − 8αn)2
4α2m2
(101)
>
√
4αm2n
4α2m2
(102)
=
√
n
α
= Xc, (103)
hence confirming that Xc < X+. We now use the second derivative to confirm there is a
sign change at each of the points. We can see as X → 0+, we have d2 Abound/d Z2 > 0.
Taking Xˆ− = 4n/m as a point between X− and Xc, we evaluate
d2 Abound
dZ2
∣∣∣∣
X=Xˆ−
= −12n
3(m2 − 16αn)2
m4
< 0; (104)
thus, we can confirm there is an inflection point at X− with the curve changing from
convex to concave. Taking Xˆ+ = (m2 − 8αn)/2αm as a point between Xc and X+,
we evaluate
d2 Abound
dZ2
∣∣∣∣
X=Xˆ−
= (m
2 − 8αn)((m2 − 8αn)2 − 4αm2n)2
32α3m4
> 0; (105)
hence, there is a sign change at the point Xc with the curve changing from convex to
concave. Finally, taking the limit as X → ∞, we see that d2 Abound/d Z2 < 0; thus,
we have a third inflection point with the curve changing from convex to concave. So
to conclude, under the conditions 16α(1 + Y + βY 2) < (1 + γ Y )2, we have three
inflection points.
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H Computational Construction of Time Courses for Single-Ligand
Dynamics–MATLAB Code
1 %constants and parameters:
2 %-------------------------
3 kap=1e7;kam =0.1;
4 ap=2;am =0.01;
5 Dt=1e-10;
6 A=1e-8;
7
8 %time span
9 %-------------------------
10 t=linspace (0 ,100 ,200) ’;
11
12 %find the eigenvalues and solve the system
13 %-------------------------
14 Tr=-(kam+kap*A+ap*kap*A)-am*kam; %trace of M
15 Det=(-(kam+kap*A+ap*kap*A))*(-am*kam)-(am*kam
-kap*A)*(ap*kap*A); %determinant of M
16 r1=(Tr+sqrt(Tr^2-4*Det))/2; %eigenvalue 1
17 r2=(Tr -sqrt(Tr^2-4*Det))/2; %eigenvalue 2
18
19 AR=(kap*A*Dt)/Det *((r2*(am*kam+r1)*exp(r1*t)-
r1*(am*kam+r2)*exp(r2*t))/(r1 -r2)+am*kam)
;
20 ARA=(ap*kap ^2*A^2*Dt)/(Det*(r1 -r2))*((r2*exp(
r1*t)-r1*exp(r2*t))+r1 -r2);
21 R=Dt -AR -ARA;
Listing 1 SingleAnalytical.m
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